Published TCIMAIL newest issue No.196
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 41859-67-0 | Product Number: B3346
Bezafibrate
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]isobutyric Acid
Product Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
|---|---|---|---|---|
| 5G |
€77.00
|
2 | 32 |
|
| 25G |
€249.00
|
1 | 17 |
|
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
| Product Number | B3346 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__1__9H__2__0ClNO__4 = 361.82 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| CAS RN | 41859-67-0 |
| Reaxys Registry Number | 4267656 |
| PubChem Substance ID | 87560846 |
| Merck Index (14) | 1195 |
| MDL Number | MFCD00078970 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Melting point | 182.0 to 186.0 °C |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 184 °C |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H302 : Harmful if swallowed. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. |
Related Laws:
| EC Number | 255-567-9 |
| RTECS# | UE8755000 |
Transport Information:
| HS Number | 2924297099 |
Application
Bezafibrate: Antilipemic with Activity against Peroxisome Proliferator-Activated Receptors (PPARs)
The fibrates, including bezafibrate, clofibrate [C0941], clinofibrate [C3100] and fenofibrate [F0674] are lower elevated serum lipids by decreasing the low density lipoprotein (LDL) fraction rich in cholesterol and the very low density lipoprotein (VLDL) fraction rich in triglycerides. In addition, fibrates increase the high density lipoprotein (HDL) cholesterol fraction. The precise mechanisms of action remain unknown, but it has been reported that the major modes of action of the fibrates as follows: VLDL catabolism by increased lipoprotein and hepatic triglyceride lipase activities; suppression of triglyceride biosynthesis by acetyl-CoA carboxylase enzyme inhibition and attenuation of cholesterol biosynthesis by inhibition of the rate-limiting HMG-CoA reductase.
Since the late 1990s, it has been reported that fibrates activate specific transcription factors belonging to the nuclear hormone receptor superfamily, termed peroxisome proliferator-activated receptors (PPARs) which activation increases HDL cholesterol synthesis, stimulates "reverse" cholesterol transport and reduces triglycerides. (The product is for research purpose only.)
Since the late 1990s, it has been reported that fibrates activate specific transcription factors belonging to the nuclear hormone receptor superfamily, termed peroxisome proliferator-activated receptors (PPARs) which activation increases HDL cholesterol synthesis, stimulates "reverse" cholesterol transport and reduces triglycerides. (The product is for research purpose only.)
References
- Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects
- Bezafibrate inhibits HMG-CoA reductase activity in incubated blood mononuclear cells from normal subjects and patients with heterozygous familial hypercholesterolaemia
- Bezafibrate: An update of its pharmacology and use in the management of dyslipidemia (a review)
- Mechanism of action of fibrates on lipid and lipoprotein metabolism (a review)
- Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons (a review)
- Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? (a review)
PubMed Literature
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.